GHRP-2

What is GHRP-2?

GHRP-2 is a synthetic growth hormone secretagogue, a peptide built to make the pituitary gland release its own growth hormone.

It belongs to the growth hormone-releasing peptide (GHRP) family, and GHRP-6 is its close relative in that family. These peptides are grouped as "secretagogues" because they prompt secretion of a hormone the body already makes, rather than replacing that hormone directly. GHRP-2 has been described in research settings both as a GH secretagogue and as a probe in growth-hormone provocative testing, though published detail is limited. It is a research compound, not an approved medicine.

How does GHRP-2 work?

GHRP-2 binds the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor, and triggers a short pulse of GH from the anterior pituitary.

The GH axis has two main "on switches." GHRH (growth hormone-releasing hormone) acts on the GHRH receptor, and ghrelin and the GHRPs act on GHS-R. GHRP-2 sits on the ghrelin side. Because that receptor is the ghrelin receptor, activating it also carries ghrelin-linked signals, which is why appetite is part of the picture with this class.

The two mechanisms behave differently over time. GHRP-2 produces a short-acting pulse. By contrast, a long-acting GHRH analog such as CJC-1295 produced sustained increases in GH and IGF-1 rather than a brief spike (Teichman et al., 2006). That difference in duration is why GHRH analogs and GHRPs are often studied as two separate levers on the same axis.

How is GHRP-2 different from ipamorelin?

The key difference is selectivity: ipamorelin releases GH without meaningfully raising ACTH, cortisol, or prolactin (Raun et al., 1998), while GHRP-2 has been reported to also raise cortisol and prolactin.

Raun et al. (1998) described ipamorelin as a GHRP-class peptide with GH-release selectivity closer to GHRH, specifically noting it did not increase ACTH or cortisol at doses that released GH. That selectivity is the reason ipamorelin is often described as the more targeted option. GHRP-2, one of the earlier peptides in the family, is generally reported to keep more of the off-target pituitary stimulation typical of the original GHRPs, though controlled human comparisons are limited.

For contrast, a long-acting GHRH analog, CJC-1295, produced sustained rises in GH and IGF-1 rather than a short pulse (Teichman et al., 2006).

What does research report about GHRP-2 dosing?

This page does not provide GHRP-2 dosing instructions, and there is no controlled human dose-ranging trial data specific to GHRP-2 that can be cited here.

Published detail on GHRP-2 comes largely from early pharmacology and growth-hormone provocative-testing research rather than large modern dose-finding trials, and those older reports do not amount to a validated dosing protocol. Because that evidence base is thin and a personal dose depends on health history, goals, labs, and other factors, the appropriate dose is a decision for a qualified clinician, not a number to copy from a page. Anyone comparing GHRP-2 with related peptides should read published research as "what was studied," not as a personal protocol.

What is GHRP-2's half-life?

GHRP-2 is short-acting and produces a brief GH pulse rather than a sustained increase.

This short window is the practical difference from the long-acting GHRH analogs. Where CJC-1295 was reported to hold GH and IGF-1 up over an extended period (Teichman et al., 2006), a GHRP like GHRP-2 acts more like a single push on the pituitary that fades. Precise pharmacokinetic values for GHRP-2 are not well established in large human trials, so treat any single number you see elsewhere with caution.

What are the side effects reported with GHRP-2?

Reported effects cluster around two things: the peptide's ghrelin-receptor activity and its less-selective action on the pituitary.

• Appetite and hunger. As a ghrelin mimetic, GHRP-2 can increase hunger, an effect expected from GHS-R activation.
• Cortisol and prolactin. Unlike ipamorelin, which did not meaningfully raise ACTH, cortisol, or prolactin (Raun et al., 1998), the earlier GHRPs including GHRP-2 have been reported to raise cortisol and prolactin, though controlled long-term data is limited.
• Blood sugar and insulin. This is a class-level caution, not a GHRP-2-specific finding: the orally active ghrelin-receptor secretagogue MK-677 raised fasting glucose and lowered insulin sensitivity in older adults over 12 months (Nass et al., 2008).
• Water retention and injection-site reactions are commonly described with GH-axis peptides, though controlled long-term safety data for GHRP-2 itself is limited.

Because human safety data specific to GHRP-2 is limited, these points describe what research and the related class report, not a full safety profile.

How does GHRP-2 compare to GHRP-6?

Both are ghrelin-receptor secretagogues from the same GHRP family, and both raise GH through GHS-R.

The commonly described difference is emphasis: GHRP-6 is noted for a strong appetite and hunger effect, while GHRP-2 is described as a comparatively more potent GH releaser with a milder appetite push. These comparisons come from older observational and pharmacology reports rather than controlled head-to-head trials, so treat them as general description. Both are less selective than ipamorelin, which stands apart for releasing GH without meaningfully raising cortisol or prolactin (Raun et al., 1998). See the GHRP-6 and ipamorelin pages for side-by-side detail.

What is the research status of GHRP-2?

GHRP-2 is a research peptide, not an approved medicine, and long-term controlled human trials are limited.

Much of what is written about it draws on early pharmacology, the ghrelin-receptor class, and comparisons with related peptides rather than large modern outcome studies specific to GHRP-2. That is exactly why careful framing matters: research shows what has been observed, but it does not promise a result for any individual, and it does not replace a clinician's judgment.